veru inc shares were down 20 to 1146 after the company said the food and drug administration informed it of an updated meeting date nov 9 with its pulmonaryallergy drugs advisory committee the meeting was scheduled to discuss verus request for emergency use authorization of sabizabulin for hospitalized covid19 patients who are at high risk for acute respiratory distress syndrome veru said that although the meeting has been rescheduled to nov 9 the agenda hasnt changed according to the notification published in the federal register the stock is still up 101 year to date the meeting was originally scheduled for oct 6